Karuna Therapeutics Valuation
Is KRTX * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of KRTX * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: KRTX * (MX$3226.17) is trading below our estimate of fair value (MX$11112.01)
Significantly Below Fair Value: KRTX * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for KRTX *?
Other financial metrics that can be useful for relative valuation.
What is KRTX *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$12.22b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 16774.7x |
Enterprise Value/EBITDA | -22.3x |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does KRTX *'s PB Ratio compare to its peers?
Company | Forward PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 3.7x | ||
INCY Incyte | 2.2x | 17.8% | US$12.2b |
603392 Beijing Wantai Biological Pharmacy Enterprise | 6.8x | 63.0% | CN¥87.1b |
UTHR United Therapeutics | 2.2x | 6.7% | US$11.8b |
EXAS Exact Sciences | 3.5x | 61.9% | US$11.3b |
KRTX * Karuna Therapeutics | 9.7x | 60.0% | Mex$12.2b |
Price-To-Book vs Peers: KRTX * is expensive based on its Price-To-Book Ratio (9.7x) compared to the peer average (2.8x).
Price to Earnings Ratio vs Industry
How does KRTX *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Book vs Industry: KRTX * is expensive based on its Price-To-Book Ratio (9.7x) compared to the Global Biotechs industry average (2.5x).
Price to Book Ratio vs Fair Ratio
What is KRTX *'s PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | 9.7x |
Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate KRTX *'s Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.